Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
doxorubicin + vinflunine
- Development stage
- Unknown
- Lead developer
- Pierre Fabre
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Doxorubicin + vinflunine is an investigational combination chemotherapy regimen composed of two cytotoxic agents used in the treatment of cancer. Doxorubicin is an anthracycline antibiotic that exerts its antitumor effects primarily through DNA intercalation and inhibition of topoisomerase II, leading to DNA damage and generation of reactive oxygen species. Vinflunine is a third-generation vinca alkaloid that inhibits microtubule assembly by binding to tubulin, thereby disrupting mitotic spindle formation and arresting cell division. The combination has been evaluated in phase I clinical studies for safety, pharmacokinetics, and preliminary efficacy in patients with advanced solid tumors[1][4][7]. Both drugs are small molecules with established roles as antineoplastic agents.
- Brand names
- DoxilMyocetZolsketil Pegylated Liposomal
- Other names
- DXR + VFL
02
Targets
TOP2A (DNA topoisomerase II)DNASRI (Soluble Resistance-related Calcium-binding protein)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on doxorubicin + vinflunine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on doxorubicin + vinflunine.